Retaspimycin HCl (IPI-504)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Retaspimycin HCl (IPI-504), covering 2014-11-13 to 2014-11-13. Get the full timeline:
Most recent: Clinical Trial Update: Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer [Phase 1, Phase 2]